Ebola vaccines in clinical trial: The promising candidates

Human Vaccines and Immunotherapeutics

Volumn 13, Issue 1, 2017, Pages 153-168

  Wang, Yuxiao ^a   Li, Jingxin ^b   Hu, Yuemei ^b   Liang, Qi ^b   Wei, Mingwei ^c   Zhu, Fengcai ^b  

^a SOUTHEAST UNIVERSITY   (China)

^b JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

clinical trial; Ebola virus; efficacy; immunogenicity; safety; vaccine

Indexed keywords

ADENOVIRUS VECTOR; DNA VACCINE; EBOLA VACCINE; REPLICATIVE VECTOR BASED EBOLA VACCINE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; GENE EXPRESSION; HUMAN; IMMUNOGENICITY; OPEN STUDY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; VACCINATION; VACCINE IMMUNOGENICITY; VIRUS ATTACHMENT; VIRUS MORPHOLOGY; VIRUS REPLICATION; VIRUS TRANSCRIPTION; CLINICAL TRIAL (TOPIC); HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY;

CLINICAL TRIALS AS TOPIC; EBOLA VACCINES; HEMORRHAGIC FEVER, EBOLA; HUMANS;

EID: 85010716237     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1225637     Document Type: Review

References (91)

1. Rimoin AW, Hotez PJ. NTDs in the heart of darkness:the Democratic Republic of Congo's unknown burden of neglected tropical diseases. PLoS Negl Trop Dis 2013; 7:e2118; PMID:23936557; http://dx.doi.org/10.1371/journal.pntd.0002118
2. Towner JS, Sealy TK, Khristova ML, Albarino CG, Conlan S, Reeder SA, Quan PL, Lipkin WI, Downing R, Tappero JW, et al. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 2008; 4:e1000212; PMID:19023410; http://dx.doi.org/10.1371/journal.ppat.1000212
3. Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 2004; 4:487-98; PMID:15288821; http://dx.doi.org/10.1016/S1473-3099(04)01103-X
4. Pourrut X, Kumulungui B, Wittmann T, Moussavou G, Delicat A, Yaba P, Nkoghe D, Gonzalez JP, Leroy EM. The natural history of Ebola virus in Africa. Microbes infect 2005; 7:1005-14; PMID:16002313; http://dx.doi.org/10.1016/j.micinf.2005.04.006
5. Reed DS, Mohamadzadeh M. Status and challenges of filovirus vaccines. Vaccine 2007; 25:1923-34; PMID:17241710; http://dx.doi.org/10.1016/j.vaccine.2006.11.037
6. World Health Organization. Ebola virus disease fact sheets. Available at:http://www.who.int/mediacentre/factsheets/fs103/en/. Access:May27, 2016.
7. World Health Organization. Ebola virus disease outbreak. Available at:http://www.who.int/csr/disease/ebola/en/. Access:June10, 2016.
8. Sridhar S. Clinical development of Ebola vaccines. Ther Adv Vaccines 2015; 3:125-38; PMID:26668751; http://dx.doi.org/10.1177/2051013615611017
9. Bukreyev A, Rollin PE, Tate MK, Yang L, Zaki SR, Shieh WJ, Murphy BR, Collins PL, Sanchez A. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 2007; 81:6379-88; PMID:17428868; http://dx.doi.org/10.1128/JVI.00105-07
10. Beniac DR, Melito PL, Devarennes SL, Hiebert SL, Rabb MJ, Lamboo LL, Jones SM, Booth TF. The organisation of Ebola virus reveals a capacity for extensive, modular polyploidy. PloS one 2012; 7:e29608; PMID:22247782; http://dx.doi.org/10.1371/journal.pone.0029608
11. Audet J, Kobinger GP. Immune evasion in ebolavirus infections. Viral Immunol 2015; 28:10-8; PMID:25396298; http://dx.doi.org/10.1089/vim.2014.0066
12. Geisbert TW, Daddario-Dicaprio KM, Lewis MG, Geisbert JB, Grolla A, Leung A, Paragas J, Matthias L, Smith MA, Jones SM, et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog 2008; 4:e1000225; PMID:19043556; http://dx.doi.org/10.1371/journal.ppat.1000225
13. Geisbert TW, Daddario-DiCaprio KM, Williams KJ, Geisbert JB, Leung A, Feldmann F, Hensley LE, Feldmann H, Jones SM. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 2008; 82:5664-8; PMID:18385248; http://dx.doi.org/10.1128/JVI.00456-08
14. Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, Grolla A, Feldmann H. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol 2009; 83:7296-304; PMID:19386702; http://dx.doi.org/10.1128/JVI.00561-09
15. ClinicalTrial.gov. Clinical trials found for Ebola vaccine. Available at:https://clinicaltrials.gov/ct2/results?term=Ebola+vaccine&Search=Search. Access:June10, 2016.
16. Basler CF, Wang X, Muhlberger E, Volchkov V, Paragas J, Klenk HD, Garcia-Sastre A, Palese P. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A 2000; 97:12289-94; PMID:11027311; http://dx.doi.org/10.1073/pnas.220398297
17. Pushko P, Bray M, Ludwig GV, Parker M, Schmaljohn A, Sanchez A, Jahrling PB, Smith JF. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 2000; 19:142-53; PMID:10924796
18. Wilson JA, Hart MK. Protection from Ebola Virus Mediated by Cytotoxic T Lymphocytes Specific for the Viral Nucleoprotein. J Virol 2001; 75:2660-4; PMID:11222689; http://dx.doi.org/10.1128/JVI.75.6.2660-2664.2001
19. Herbert AS, Kuehne AI, Barth JF, Ortiz RA, Nichols DK, Zak SE, Stonier SW, Muhammad MA, Bakken RR, Prugar LI, et al. Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Protects Nonhuman Primates from Intramuscular and Aerosol Challenge with ebolavirus. J Virol 2013; 87:4952-64; PMID:23408633; http://dx.doi.org/10.1128/JVI.03361-12
20. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000; 408:605-9; PMID:11117750; http://dx.doi.org/10.1038/35046108
21. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M, Koup RA, Jahrling PB, Nabel GJ. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003; 424:681-4; PMID:12904795; http://dx.doi.org/10.1038/nature01876
22. Sullivan NJ, Hensley L, Asiedu C, Geisbert TW, Stanley D, Johnson J, Honko A, Olinger G, Bailey M, Geisbert JB, et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 2011; 17:1128-31; PMID:21857654; http://dx.doi.org/10.1038/nm.2447
23. Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010; 29:304-13; PMID:21034824; http://dx.doi.org/10.1016/j.vaccine.2010.10.037
24. Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, Lamoreaux L, Custers JH, Popernack PM, Yang ZY, Pau MG, et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 2006; 3:e177; PMID:16683867; http://dx.doi.org/10.1371/journal.pmed.0030177
25. Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, Novitsky V, Mbewe B, Pitisuttithum P, Schechter M, Vardas E, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies:correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 2010; 28:950-7; PMID:16683867; http://dx.doi.org/10.1371/journal.pmed.0030177
26. Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, Truitt DM, Sumida SM, Kishko MG, Arthur JC, et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004; 172:6290-7; PMID:15128818
27. Kobinger GP, Feldmann H, Zhi Y, Schumer G, Gao G, Feldmann F, Jones S, Wilson JM. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 2006; 346:394-401; PMID:16356525; http://dx.doi.org/10.1016/j.virol.2005.10.042
28. Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D, Honko A, Johnson J, Mulangu S, Pau MG, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol 2011; 85:4222-33; PMID:21325402; http://dx.doi.org/10.1128/JVI.02407-10
29. Zahn R, Gillisen G, Roos A, Koning M, van der Helm E, Spek D, Weijtens M, Grazia Pau M, Radosevic K, Weverling GJ, et al. Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species. PloS one 2012; 7:e44115; PMID:23236343; http://dx.doi.org/10.1371/journal.pone.0044115
30. Milligan ID, Gibani MM, Sewell R, Clutterbuck EA, Campbell D, Plested E, Nuthall E, Voysey M, Silva-Reyes L, McElrath MJ, et al. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines:A Randomized Clinical Trial. Jama 2016; 315:1610-23; PMID:27092831; http://dx.doi.org/10.1001/jama.2016.4218
31. Zhu FC, Hou LH, Li JX, Wu SP, Liu P, Zhang GR, Hu YM, Meng FY, Xu JJ, Tang R, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China:preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 2015; 385:2272-9; PMID:25817373; http://dx.doi.org/10.1016/S0140-6736(15)60553-0
32. Kibuuka H, Berkowitz NM, Millard M, Enama ME, Tindikahwa A, Sekiziyivu AB, Costner P, Sitar S, Glover D, Hu Z, et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults:a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet 2015; 385:1545-54; PMID:25540891; http://dx.doi.org/10.1016/S0140-6736(14)62385-0
33. Rampling T, Ewer K, Bowyer G, Wright D, Imoukhuede EB, Payne R, Hartnell F, Gibani M, Bliss C, Minhinnick A, et al. A Monovalent Chimpanzee Adenovirus Ebola Vaccine - Preliminary Report. N Engl J Med 2015; 374(17):1635-46; PMID:25629663; http://dx.doi.org/10.1056/NEJMoa1411627
34. Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC, Hensley L, Ammendola V, Abbate A, Grazioli F, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med 2014; 20:1126-9; PMID:25194571; http://dx.doi.org/10.1038/nm.3702
35. Ledgerwood JE, DeZure AD, Stanley DA, Novik L, Enama ME, Berkowitz NM, Hu Z, Joshi G, Ploquin A, Sitar S, et al. Chimpanzee Adenovirus Vector Ebola Vaccine - Preliminary Report. N Engl J Med 2014; PMID:25426834; http://dx.doi.org/10.1056/NEJMoa1410863
36. Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Translational Med 2012; 4:115ra1; PMID:22218690; http://dx.doi.org/10.1126/scitranslmed.3003155
37. Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, Imoukhuede EB, Payne R, Fehling SK, Strecker T, et al. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. N Engl J Med 2016; 374:1635-46; PMID:25629663; http://dx.doi.org/10.1056/NEJMoa1411627
38. De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G, Cochet C, Estoppey D, Steiner-Monard V, Lonchampt S, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults:a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis 2016; 16:311-20; PMID:26725450; http://dx.doi.org/10.1016/S1473-3099(15)00486-7
39. Tapia MD, Sow SO, Lyke KE, Haidara FC, Diallo F, Doumbia M, Traore A, Coulibaly F, Kodio M, Onwuchekwa U, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo:a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2016; 16:31-42; PMID:26546548; http://dx.doi.org/10.1016/S1473-3099(15)00362-X
40. Chepurnov AA, Ternovoi VA, Dadaeva AA, Dmitriev IP, Sizikova LP, Volchkov VE, Kudoiarova NM, Rudzevich TN, Netesov SV. Immunobiological properties of vp24 protein of Ebola virus expressed by recombinant vaccinia virus. Voprosy virusologii 1997; 42:115-20; PMID:9297340
41. Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 2002; 8:503-7; PMID:11996686; http://dx.doi.org/10.3201/eid0805.010284
42. Pijlman GP, Suhrbier A, Khromykh AA. Kunjin virus replicons:an RNA-based, non-cytopathic viral vector system for protein production, vaccine and gene therapy applications. Exp Opin Biol Ther 2006; 6:135-45; PMID:16436039; http://dx.doi.org/10.1517/14712598.6.2.135
43. Reynard O, Mokhonov V, Mokhonova E, Leung J, Page A, Mateo M, Pyankova O, Georges-Courbot MC, Raoul H, Khromykh AA, et al. Kunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection. J Infect Dis 2011; 204 Suppl 3:S1060-5; PMID:21987742; http://dx.doi.org/10.1093/infdis/jir347
44. Pyankov OV, Bodnev SA, Pyankova OG, Solodkyi VV, Pyankov SA, Setoh YX, Volchkova VA, Suhrbier A, Volchkov VV, Agafonov AA, et al. A Kunjin Replicon Virus-like Particle Vaccine Provides Protection Against Ebola Virus Infection in Nonhuman Primates. J Infect Dis 2015; 212 Suppl 2:S368-71; PMID:25732811; http://dx.doi.org/10.1093/infdis/jiv019
45. Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Moller P, Wagner R, Volchkov V, Klenk HD, Feldmann H, Stroher U. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004; 78:5458-65; PMID:15113924;
46. Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005; 11:786-90; PMID:15937495; http://dx.doi.org/10.1038/nm1258
47. Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Stroher U, Grolla A, Bray M, Fritz EA, Fernando L, Feldmann F, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog 2007; 3:e2; PMID:17238284; http://dx.doi.org/10.1371/journal.ppat.0030002
48. Qiu X, Fernando L, Alimonti JB, Melito PL, Feldmann F, Dick D, Stroher U, Feldmann H, Jones SM. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PloS one 2009; 4:e5547; PMID:19440245; http://dx.doi.org/10.1371/journal.pone.0005547
49. Tuffs A. Experimental vaccine may have saved Hamburg scientist from Ebola fever. BMJ 2009; 338:b1223; PMID:19307268
50. Geisbert TW, Hensley LE, Geisbert JB, Leung A, Johnson JC, Grolla A, Feldmann H. Postexposure treatment of Marburg virus infection. Emerg Infect Dis 2010; 16:1119-22; PMID:20587184; http://dx.doi.org/10.3201/eid1607.100159
51. Tsuda Y, Safronetz D, Brown K, LaCasse R, Marzi A, Ebihara H, Feldmann H. Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection. J Infect Dis 2011; 204 Suppl 3:S1090-7; PMID:21987746; http://dx.doi.org/10.1093/infdis/jir379
52. Wong G, Audet J, Fernando L, Fausther-Bovendo H, Alimonti JB, Kobinger GP, Qiu X. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine 2014; 32:5722-9; PMID:25173474; http://dx.doi.org/10.1016/j.vaccine.2014.08.028
53. Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, et al. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe - Preliminary Report. N Engl J Med 2016; 374:1647-60; PMID:25830326; http://dx.doi.org/10.1056/NEJMoa1502924
54. Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine:a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis 2015; 15:1156-66; PMID:26248510; http://dx.doi.org/10.1016/S1473-3099(15)00154-1
55. Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Munoz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, et al. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine - Preliminary Report. N Engl J Med 2015; PMID:25830322; http://dx.doi.org/10.1056/NEJMoa1414216
56. Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, Carroll MW, Doumbia M, Draguez B, Duraffour S, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein:interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 2015; 386:857-66; PMID:26248676; http://dx.doi.org/10.1016/S0140-6736(15)61117-5
57. Wells CR, Tchuenche JM, Meyers LA, Galvani AP, Bauch CT. Impact of imitation processes on the effectiveness of ring vaccination. Bull Mathematical Biol 2011; 73:2748-72; PMID:21409511; http://dx.doi.org/10.1007/s11538-011-9646-4
58. Lai L, Davey R, Beck A, Xu Y, Suffredini AF, Palmore T, Kabbani S, Rogers S, Kobinger G, Alimonti J, et al. Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick. Jama 2015; 313:1249-55; PMID:25742465; http://dx.doi.org/10.1001/jama.2015.1995
59. Bukreyev A, Yang L, Zaki SR, Shieh WJ, Rollin PE, Murphy BR, Collins PL, Sanchez A. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol 2006; 80:2267-79; PMID:16474134; http://dx.doi.org/10.1128/JVI.80.5.2267-2279.2006
60. Yano T, Fukuta M, Maeda C, Akachi S, Matsuno Y, Yamadera M, Kobayashi A, Nagai Y, Kusuhara H, Kobayashi T, et al. Epidemiological investigation and seroprevalence of human parainfluenza virus in Mie Prefecture in Japan during 2009-2013. Jpn J Infect Dis 2014; 67:506-8; PMID:25410571
61. Bukreyev A, Marzi A, Feldmann F, Zhang L, Yang L, Ward JM, Dorward DW, Pickles RJ, Murphy BR, Feldmann H, et al. Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology 2009; 383:348-61; PMID:19010509; http://dx.doi.org/10.1016/j.virol.2008.09.030
62. Tsuda Y, Caposio P, Parkins CJ, Botto S, Messaoudi I, Cicin-Sain L, Feldmann H, Jarvis MA. A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. PLoS Negl Trop Dis 2011; 5:e1275; PMID:21858240; http://dx.doi.org/10.1371/journal.pntd.0001275
63. Klyushnenkova EN, Kouiavskaia DV, Parkins CJ, Caposio P, Botto S, Alexander RB, Jarvis MA. A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer. J Immunother 2012; 35:390-9; PMID:22576344; http://dx.doi.org/10.1097/CJI.0b013e3182585d50
64. Tierney R, Nakai T, Parkins CJ, Caposio P, Fairweather NF, Sesardic D, Jarvis MA. A single-dose cytomegalovirus-based vaccine encoding tetanus toxin fragment C induces sustained levels of protective tetanus toxin antibodies in mice. Vaccine 2012; 30:3047-52; PMID:22414558; http://dx.doi.org/10.1016/j.vaccine.2012.02.043
65. Xu G, Smith T, Grey F, Hill AB. Cytomegalovirus-based cancer vaccines expressing TRP2 induce rejection of melanoma in mice. Biochem Biophys Res Commun 2013; 437:287-91; PMID:23811402; http://dx.doi.org/10.1016/j.bbrc.2013.06.068
66. Ohimain EI. Recent advances in the development of vaccines for Ebola virus disease. Virus Res 2016; 211:174-85; PMID:26596227; http://dx.doi.org/10.1016/j.virusres.2015.10.021
67. Papaneri AB, Wirblich C, Cann JA, Cooper K, Jahrling PB, Schnell MJ, Blaney JE. A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence. Virology 2012; 434:18-26; PMID:22889613; http://dx.doi.org/10.1016/j.virol.2012.07.020
68. Blaney JE, Wirblich C, Papaneri AB, Johnson RF, Myers CJ, Juelich TL, Holbrook MR, Freiberg AN, Bernbaum JG, Jahrling PB, et al. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol 2011; 85:10605-16; PMID:21849459; http://dx.doi.org/10.1128/JVI.00558-11
69. Blaney JE, Marzi A, Willet M, Papaneri AB, Wirblich C, Feldmann F, Holbrook M, Jahrling P, Feldmann H, Schnell MJ. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog 2013; 9:e1003389; PMID:23737747; http://dx.doi.org/10.1371/journal.ppat.1003389
70. Cleaveland S, Fevre EM, Kaare M, Coleman PG. Estimating human rabies mortality in the United Republic of Tanzania from dog bite injuries. Bulletin of the World Health Organization 2002; 80:304-10; PMID:12075367
71. Knobel DL, du Toit JT, Bingham J. Development of a bait and baiting system for delivery of oral rabies vaccine to free-ranging African wild dogs (Lycaon pictus). J Wildlife Dis 2002; 38:352-62; PMID:12038135; http://dx.doi.org/10.7589/0090-3558-38.2.352
72. Lupton HW, Lambert RD, Bumgardner DL, Moe JB, Eddy GA. Inactivated vaccine for Ebola virus efficacious in guineapig model. Lancet 1980; 2:1294-5; PMID:6108462
73. Rao M, Bray M, Alving CR, Jahrling P, Matyas GR. Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus:protection in mice requires CD4(+) T cells. J Virol 2002; 76:9176-85; PMID:12186901
74. Xu L, Sanchez A, Yang Z, Zaki SR, Nabel EG, Nichol ST, Nabel GJ. Immunization for Ebola virus infection. Nat Med 1998; 4:37-42; PMID:9427604
75. Vanderzanden L, Bray M, Fuller D, Roberts T, Custer D, Spik K, Jahrling P, Huggins J, Schmaljohn A, Schmaljohn C. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 1998; 246:134-44; PMID:9657001
76. Grant-Klein RJ, Van Deusen NM, Badger CV, Hannaman D, Dupuy LC, Schmaljohn CS. A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge. Hum Vaccin Immunother 2012; 8:1703-6; PMID:22922764; http://dx.doi.org/10.4161/hv.21873
77. Ebihara H, Zivcec M, Gardner D, Falzarano D, LaCasse R, Rosenke R, Long D, Haddock E, Fischer E, Kawaoka Y, et al. A Syrian golden hamster model recapitulating ebola hemorrhagic fever. J Infect Dis 2013; 207:306-18; PMID:23045629; http://dx.doi.org/10.1093/infdis/jis626
78. Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, Bailer RT, Chakrabarti BK, Bailey MA, Gomez PL, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006; 13:1267-77; PMID:16988008; http://dx.doi.org/10.1128/CVI.00162-06
79. Sarwar UN, Costner P, Enama ME, Berkowitz N, Hu Z, Hendel CS, Sitar S, Plummer S, Mulangu S, Bailer RT, et al. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis 2015; 211:549-57; PMID:25225676; http://dx.doi.org/10.1093/infdis/jiu511
80. Bavari S, Bosio CM, Wiegand E, Ruthel G, Will AB, Geisbert TW, Hevey M, Schmaljohn C, Schmaljohn A, Aman MJ. Lipid raft microdomains:a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med 2002; 195:593-602; PMID:11877482
81. Warfield KL, Bosio CM, Welcher BC, Deal EM, Mohamadzadeh M, Schmaljohn A, Aman MJ, Bavari S. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A 2003; 100:15889-94; PMID:14673108; http://dx.doi.org/10.1073/pnas.2237038100
82. Warfield KL, Swenson DL, Negley DL, Schmaljohn AL, Aman MJ, Bavari S. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine 2004; 22:3495-502; PMID:15308377; http://dx.doi.org/10.1016/j.vaccine.2004.01.063
83. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007; 196 Suppl 2:S430-7; PMID:17940980
84. Sun Y, Carrion R, Jr., Ye L, Wen Z, Ro YT, Brasky K, Ticer AE, Schwegler EE, Patterson JL, Compans RW, et al. Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology 2009; 383:12-21; PMID:18986663; http://dx.doi.org/10.1016/j.virol.2008.09.020
85. Warfield KL, Dye JM, Wells JB, Unfer RC, Holtsberg FW, Shulenin S, Vu H, Swenson DL, Bavari S, Aman MJ. Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles. PloS one 2015; 10:e0118881; PMID:25793502; http://dx.doi.org/10.1371/journal.pone.0118881
86. Halfmann P, Kim JH, Ebihara H, Noda T, Neumann G, Feldmann H, Kawaoka Y. Generation of biologically contained Ebola viruses. Proc Natl Acad Sci U S A 2008; 105:1129-33; PMID:18212124; http://dx.doi.org/10.1073/pnas.0708057105
87. Hoenen T, Groseth A, de Kok-Mercado F, Kuhn JH, Wahl-Jensen V. Minigenomes, transcription and replication competent virus-like particles and beyond:reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever viruses. Antiviral Research 2011; 91:195-208; PMID:21699921; http://dx.doi.org/10.1016/j.antiviral.2011.06.003
88. Halfmann P, Ebihara H, Marzi A, Hatta Y, Watanabe S, Suresh M, Neumann G, Feldmann H, Kawaoka Y. Replication-deficient ebolavirus as a vaccine candidate. J Virol 2009; 83:3810-5; PMID:19211761; http://dx.doi.org/10.1128/JVI.00074-09
89. Marzi A, Halfmann P, Hill-Batorski L, Feldmann F, Shupert WL, Neumann G, Feldmann H, Kawaoka Y. Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates. Science 2015; 348:439-42; PMID:25814063; http://dx.doi.org/10.1126/science.aaa4919
90. Ewer KJ, Lambe T, Rollier CS, Spencer AJ, Hill AV, Dorrell L. Viral vectors as vaccine platforms:from immunogenicity to impact. Curr Opin Immunol 2016; 41:47-54; PMID:27286566; http://dx.doi.org/10.1016/j.coi.2016.05.014
91. Parpia AS, Ndeffo-Mbah ML, Wenzel NS, Galvani AP. Effects of Response to 2014-2015 Ebola Outbreak on Deaths from Malaria, HIV/AIDS, and Tuberculosis, West Africa. Emerg Infect Dis 2016; 22:433-41; PMID:26886846; http://dx.doi.org/10.3201/eid2203.150977